Lawrence F Audino, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 284 Sea Meadow Dr, Portsmouth, RI 02871 Phone: 401-293-0933 |
News Archive
A procedure intended to help heal musculoskeletal injuries called platelet-rich plasma therapy, or P.R.P., has created a big buzz in sports medicine and the media in recent years. Tiger Woods reportedly received the procedure for a sore knee and Pittsburgh Steelers' Hines Ward used it for a sprained knee ligament just before playing a key role in the team's 2009 Super Bowl victory.
Scientists at St. Jude Children's Research Hospital, The Scripps Research Institute (TSRI) and other institutions today announced the launch of the Human Dark Proteome Initiative (HDPI). The initiative aims to accelerate research into biology's "invisible mass" to provide novel insights into cell function and a new frontier in drug discovery.
A number of Hispanic organizations have united to address major problems with the health care legislation passed in the U.S. House of Representatives and urge the Senate to come up with a bipartisan solution for real healthcare reform. They are especially concerned the health care legislation will create a greater tax burden and unfair government mandates on Hispanic small businesses and families. During this critical health care debate, these organizations want their voices to be heard and believe that the current approach will lead to loss of jobs and reduced wages for Hispanic workers.
The credit-rating firm downgraded the outlook for health insurers from stable to negative, citing the health law's troubled rollout. Meanwhile, Aetna CEO Mark Bertolini predicted that companies would soon spend billions on consumer advertising. And The New York Times explores allegations that Health Management Associates, a for-profit hospital chain based in Naples, Fla., pursued strategies to increase admissions, regardless of whether a patient needed hospital care.
AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.
› Verified 6 days ago